Quest Diagnostics (DGX) Stock Drops Amid Medicare Reimbursement Rate Cuts
Quest Diagnostics' stock fell nearly 5% on September 22, 2026, following news that the Centers for Medicare & Medicaid Services will reduce reimbursement rates for lab work by up to 15%, effective January 1, 2027. The move is expected to save taxpayers $1 billion annually but could directly impact Quest's revenue stream. Quest receives approximately 11% of its total revenue from CMS reimbursements, meaning a full 15% rate cut would reduce annual revenue by about 1.65%. With potential successive cuts through 2029, the worst-case scenario for Quest is an overall reduction in business of slightly less than 5%, which appears to be already reflected in today's stock price drop. The company has previously highlighted reduced Medicare and Medicaid reimbursement rates as a key risk factor. Analysts suggest that with this news largely priced into the current decline, further downward movement may be limited.
Tickers: $DGX
Topics: CMS reimbursement Medicare & Medicaid Quest Diagnostics revenue impact